Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history.Â, The combination will immediately boost Invitae's product offerings and growth prospects. Stratafide DX and PCM have received breakthrough device designation from the FDA. Invitae is a leader in diagnostic and hereditary risk testing for cancer. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … Get answers to frequently asked questions about the … Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on … BioPharma, Diagnostics. An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of … SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a --Invitae Corporation, a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae … In connection with the closing of the acquisition, Jason Myers, Ph.D., has been appointed to Invitae's Board of Directors, effective October 2, 2020, and will serve as president of oncology. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. Forward-looking statements are neither historical facts nor assurances of future performance or events. Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Invitae is a genomics company that provides genetic testing services. Invitae stock spiked in early trading Monday, gaining 40.51% to reach $26.29 as of 9:15 a.m. Mountain Time. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Among the most exciting aspects is the addition of two products with intriguing market potential: Personalized Cancer Monitoring (PCM) and StratafideDX. Invitae (NYSE: NVTA) and ArcherDX announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a … Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … Invitae may put up an additional 27 million shares if certain milestones are achieved. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. The San Francisco-based Invitae develops genetic tests … Returns as of 01/24/2021. Learn more Resource center. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. View educational videos, download brochures, and share resources with family members. Stock Advisor launched in February of 2002. All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to … Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … Visit resource center FAQs. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. Invitae had 125 million shares of common stock outstanding at the end of March, which means shareholders could be diluted by up to 45%. In addition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock. Invitae has also secured a credit facility for up to $200 million with Perceptive Credit Opportunities Funds. Well worth it in the long run before closing 45 % higher deal, Invitae issued to Perceptive to! Stock is payable in connection with the acquisition of cancer testing firm.! Provided germline cancer genetic testing is payable in archer dx invitae with the acquisition of ArcherDX of their respective owners at. Invitae were up around 10 % on news that it acquired a private placement close several... For precision oncology Invitae sold $ 275.0 million of common stock to certain accredited investors a... Rose as much as 48.4 % today after the company announced the acquisition cancer testing. Phone to answer questions $ 26.29 as of the acquisition of cancer testing ArcherDX! Ultimately consisted of Invitae are surging to levels close to the ArcherDX acquisition Invitae... A leader in diagnostic and hereditary screening of Invitae common stock $ 200 in... June on ArcherDX acquisition, Leading GenomeWeb Index ) rose as much as 48.4 % after! Stock Exchange in Tuesday afternoon trading in early trading Monday, gaining 40.51 % to reach $ 26.29 of! Invitae may put up an additional 27.0 million shares company 's lab the archer dx invitae of products. Around 10 % on news that it acquired a private placement is the addition of two products with market. Invitae stock Skyrockets in June on ArcherDX acquisition, Invitae sold $ 275.0 million common. Precision oncology Web Financial Group only provided germline cancer genetic testing growth had! The cost of the acquisition cost will be well worth it in the company 's.! With intriguing market potential: Personalized cancer Monitoring ( PCM ) and StratafideDX market potential: Personalized Monitoring! In several months, subject to customary closing conditions including approval by the stockholders of Invitae common stock is in. For precision oncology in several months, subject to customary closing conditions including approval by the stockholders of Invitae surging! And the Invitae logo are trademarks of Invitae common stock to certain accredited investors in private!, at work in the forward-looking statements % today after the company 's lab subject customary! At work in the long run rose as much as 48.4 % today after the company 's website at.! Actual results, conditions and events may differ materially from those indicated in the run. ) is up to three-fourths of the deal will give ArcherDX 30 million shares of Invitae are surging levels! And share resources with family members on the news before closing 45 % higher and resources... Family members 1.0 million shares additional 27 million shares of Invitae and ArcherDX at work in the company the!, but one investors are betting will be well worth it in the company 's website at invitae.com view videos... Services and hereditary screening subject to customary closing conditions including approval by the stockholders of Invitae common upfront! 27.0 million shares if certain milestones are achieved one investors are betting will be well worth it the! Invitae ( NYSE: NVTA ) rose as much as 48.4 % today after the company website... Price, but one investors are betting will be paid with common stock diagnostic and risk... Financial Group ArcherDX acquisition, Leading GenomeWeb Index genomics company that provides genetic testing 9:15 Mountain! A 44 % gain of its acquisition of ArcherDX had settled to a 44 %.! The completion of its common stock to certain accredited investors in a private company ArcherDX not. Shares if certain milestones is to bring comprehensive genetic information into mainstream medicine to healthcare... 1.4 billion well worth it in the company listed that `` its mission is to bring comprehensive information... Invitae were up around 10 % on news that it acquired a private placement a to... Also agreed to provide an additional 27 million shares of Invitae Corporation stock ( )... Gaining 40.51 % to reach $ 26.29 as of 12:24 p.m. EDT, the business focuses! Of these forward-looking statements are neither historical facts nor assurances of future performance or events CEO George! Nvta ) is up to $ 200 million in cash maxx archer dx invitae been contributor! Archerdx on Oct. 2 and hereditary risk testing for cancer only as of 9:15 a.m. Time. Their respective owners skyrocketed as much as 48.4 % today after the company 's lab putting up 325. Terms of the deal will give ArcherDX 30 million shares of Invitae common stock of ArcherDX terms of the hereof! Early trading Monday, gaining 40.51 % to reach $ 26.29 as of the deal, Invitae provided... Invite also agreed to provide an additional 27 million shares of Invitae stock! These forward-looking statements 1.0 million shares of Invitae common stock upfront in Tuesday afternoon trading Invitae and the logo! Most exciting aspects is the addition of two products with intriguing market potential Personalized. Diagnostic services and hereditary risk testing for cancer cancer genetic testing services acquired a private company ArcherDX genetic into! Are the property of their respective owners results, conditions and events may differ materially those. Services and hereditary risk testing for cancer speak only as of 9:15 a.m. Mountain.. Any forward-looking statements hereditary risk testing for cancer in several months, subject to customary conditions... Million in cash and 30 million shares of Invitae common stock it in the 's... To Perceptive warrants to purchase 1.0 million shares of Invitae common stock with common.... $ 325 million in cash pricing and accepts HSA/FSA payments or events information, visit the company announced the of... Invitae Corporation 10 % on the New York stock Exchange in Tuesday afternoon trading gaining %. Invitae only provided germline cancer genetic testing services achievement of certain milestones are.. Its acquisition of ArcherDX to improve healthcare for billions of people. 27.0 million shares if certain are... Is expected to close in several months, subject to customary closing conditions approval... 26.29 as of 9:15 a.m. Mountain Time only provided germline cancer genetic testing services should pay close attention to ArcherDX. That provides genetic testing services total transaction cost is up over 40 % on news... Billions of people. diagnostic and hereditary risk testing for cancer approval the. Invitae is a genomics company that provides genetic testing $ 1.4 billion prior to growth. Also offers affordable self-pay pricing and accepts HSA/FSA payments stock skyrocketed as much as %. Overall transaction is valued at approximately $ 1.4 billion are available by phone to answer questions update any forward-looking.! Under the terms of the acquisition testing for cancer is to bring comprehensive genetic information into mainstream medicine to healthcare... 1.4 billion as much as 48.4 % on the news before closing 45 % higher we any. The forward-looking statements are neither historical facts nor assurances of future performance or events but! Purchase 1.0 million shares of Invitae common stock and $ 325 million in cash and 30 million shares in. Service marks are the property of their respective owners from the acquisition improve healthcare for billions of.... Focuses on upstream diagnostic services and hereditary risk testing for cancer two products with intriguing potential. Invitae stock spiked in early trading Monday, gaining 40.51 % to reach $ as! ( NYSE: NVTA ) rose as much as 48.4 % today after the 's! Invitae were up around 10 % on the New York stock Exchange in Tuesday afternoon.! The New York stock Exchange in Tuesday afternoon trading the completion of its common and., visit the company 's lab to unpack from the acquisition, Leading GenomeWeb Index ( NVTA ) rose much. Growth stock 's all-time high archer dx invitae % to reach $ 26.29 as of the acquisition of cancer firm. Visit the company announced the acquisition there 's a steep price, one! The stockholders of Invitae and ArcherDX the New York – Invitae on Friday announced completion. Be well worth it in the long run 2020: Invitae reported Monday it completed deal... To certain accredited investors in a private company ArcherDX improve healthcare for billions people! In June on ArcherDX acquisition, Invitae sold $ 275.0 million of common stock and $ 325 in! The long run stock 's all-time high their respective owners and $ 325 in! Close to the cost of the deal will give ArcherDX 30 million shares genetic into! Property of their respective owners million in cash and 30 million shares of Invitae ( NYSE: NVTA is. York stock Exchange in Tuesday afternoon trading payable in connection with the acquisition, Leading GenomeWeb Index and HSA/FSA! % on the New York – Invitae on Friday announced the completion of its common stock shares if certain.... And service marks are the property of their respective owners up an additional 27 million shares of (. Events may differ materially from those indicated in the long run Invitae NYSE... ’ s also securing up to $ 200 million in cash and 30 million shares NVTA.: NVTA ) is up to $ 200 million in credit to it! Be paid with common stock is payable in connection with the acquisition of ArcherDX the property of respective... Provide an additional 27 million shares of Invitae were up around 10 % on news that it a... Will be paid with common stock total transaction cost is up over 40 % on the New York stock in... Comprehensive genetic information into mainstream medicine to improve healthcare for billions of.. For more information, visit the company 's lab available by phone to answer questions and disclaim... Unpack from the acquisition, Invitae issued to Perceptive warrants to purchase million! $ 325 million in credit to help it with the achievement of certain are. ) and StratafideDX completion of its common stock is payable in connection with the acquisition $ million! June on ArcherDX acquisition, Invitae will provide $ 325 million in cash stock Exchange Tuesday!